Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
Ruxolitinib targets DCs: For better or worse?
Ayalew Tefferi
Hematology
Research output
:
Contribution to journal
›
Short survey
›
peer-review
7
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Ruxolitinib targets DCs: For better or worse?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
INCB018424
76%
Dendritic Cells
43%
Monocytes
20%
Antigens
15%
T-Lymphocytes
15%
Pharmaceutical Preparations
10%
Chemical Compounds
Ruxolitinib
100%
Clearance
52%
Drug
25%